Gene or Genome
Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)
decentralized clinical trials; DCT; data quality; patient diversity; remote monitoring; AI in trials; data integration; risk-based oversight; clinical trial data; regulatory guidance
Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs
Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings
Sarepta Reports Third Patient Death in Gene Therapy Studies for Limb-Girdle Muscular Dystrophy
Sarepta Therapeutics; limb-girdle muscular dystrophy; SRP-9004; gene therapy; patient death; acute liver failure; FDA clinical hold; AAV vector; Elevidys; safety concerns
Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal
Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments
RFK Jr. Removes Top HHS Aides in Major Leadership Shakeup
RFK Jr.; Health and Human Services; leadership reshuffle; chief of staff; Matt Buckham; Heather Flick Melanson; Hannah Anderson; Trump loyalists; policy shakeup
RFK Jr. Fires Top HHS Leadership in Major Department Shakeup
RFK Jr.; HHS; leadership shakeup; chief of staff replaced; Heather Flick Melanson; Hannah Anderson; Matt Buckham; health policy; White House liaison
RFK Jr. Reshuffles Top HHS Leadership, Replacing Chief of Staff and Deputy Chief
RFK Jr.; HHS; leadership shakeup; chief of staff; Heather Flick Melanson; Hannah Anderson; Matt Buckham; staff changes; federal health policy
RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS
Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson
WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)
WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval
AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma
AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines